COMBI-d: A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF(V600E/K) mutation-positive cutaneous melanoma

Autor:	Long, Georgina V. Stroyakovsky, Daniil L. Gogas, Helen and Levchenko, Eugeny de Braud, Filippo Larkin, James M. G. and Garbe, Claus Jouary, Thomas Hauschild, Axel Grob, Jean Jacques Chiarion-Sileni, Vanna Lebbe, Celeste Mandala, Mario and Millward, Michael DeMarini, Douglas James Irani, Jhangir G. and Le, Ngocdiep Casey, Michelle Patel, Kiran Flaherty, Keith
Jazyk:	angličtina
Rok vydání:	2014
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=od______2127::7f1683e4b2447fa2fc6c2adb080bc03a https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3161799 Zobrazit plný text záznamu